SOAANZ (torsemide) by PharmaIN is clinical pharmacology mechanism of action micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of henle, where it inhibits the na/k/2ci-carrier system. First approved in 2021.
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
SOAANZ (torsemide) is an oral loop diuretic that inhibits the Na/K/2Cl-carrier system in the thick ascending limb of the loop of Henle, increasing urinary excretion of sodium, chloride, and water. It is indicated for patients with edema associated with congestive heart failure, renal disease, or hepatic cirrhosis. The drug has high bioavailability (~80%) with a 3.5-hour half-life and is metabolized primarily hepatically (~80%) with renal excretion of active parent drug (~20%).
Product is at peak lifecycle stage with modest Part D spending ($5M across 10K+ claims in 2023), suggesting stable commercial performance with potential for brand team consolidation or optimization as market matures.
CLINICAL PHARMACOLOGY Mechanism of Action Micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of Henle, where it inhibits the Na/K/2CI-carrier system. Clinical pharmacology studies have confirmed this site of action in…
Worked on SOAANZ at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Loop Diuretic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moSOAANZ presents a stable career opportunity within a mature diuretic franchise with 7+ years of patent protection and modest but established revenue; roles will focus on market penetration, formulary management, and competitive defense rather than pipeline innovation. Working on this product offers predictable commercial experience in a stable therapeutic area with low clinical development demands.